National Heart, Lung, and Blood Institute; Notice of Meeting, 46879-46880 [05-15942]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 154 / Thursday, August 11, 2005 / Notices
antiviral drug-resistant mutation in a
viral protein. The medicament further
comprises a synthetic peptide that
comprises the predetermined antiviral
drug-resistant mutation and at least six
amino acid residues flanking that
mutation that are identical to the amino
acid sequence of the viral protein of the
antiviral drug-resistant virus. The
synthetic peptide induces a cytotoxic T
lymphocyte (CTL) response specific for
cells infected with the antiviral drugresistant virus. The immunostimulating
peptide may be further improved by
epitope-enhancement for inducing
specific CTLs. The antiviral protection
against drug-resistant virus shown by
compositions of the present invention
and mediated by human HLA-restricted
CTL has not been previously achieved.
Further, the compositions and methods
of this technology are useful to target
many viruses that can develop antiviral
drug resistance, including HIV–1, HIV–
2, hepatitis B virus, hepatitis C virus,
and human herpesviruses.
Design of a Novel Peptide Inhibitor of
HIV Fusion That Disrupts the Internal
Trimeric Coiled-coil of gp41
Marius G. Clore, Carole A. Bewley, and
John M. Louis (NIDDK).
U.S. Provisional Application No.
60/446,225 filed 11 Feb 2003 (HHS
Reference No. E–236–2002/0–US–01);
PCT Application No. PCT/US04/03794
filed 10 Feb 2004, which published as
WO 2004/072099 on 11 Aug 2004
(HHS Reference No. E–236–2002/0PCT–02).
Licensing Contact: Sally Hu; 301/435–
5606; e-mail: hus@mail.nih.gov.
This invention provides a peptide
derived from the sequence of the Nterminal helix (residues 546–581) of the
gp41 ectodomain of HIV–1. The peptide,
called N36Mut(e,g), contains nine
substitutions and disrupts interactions
with the C-terminal region of the gp41
ectodomain. N36Mut(e,g) inhibits HIVenvelope mediated cell fusion about
50-fold more effectively than the native
sequence (residues 546–581 of HIV–1
envelope) from which it was derived.
Thus, N36Mut(e,g) and derivatives has
potential as an anti-HIV therapeutic
agent as a HIV fusion inhibitor.
This research is described, in part, in
CA Bewley et al., ‘‘Design of a novel
peptide inhibitor of HIV fusion that
disrupts the internal trimeric coiled-coil
of gp41,’’ J. Biol. Chem. (2002 Apr 19)
277(16):14238–14245; Epub on 21 Feb
2002 as doi:10.1074/jbc.M201453200.
VerDate jul<14>2003
16:14 Aug 10, 2005
Jkt 205001
Dated: August 8, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–15939 Filed 8–10–05; 8:45 am]
46879
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SPORE in
Lung and Genitourinary Cancers.
Date: September 13–15, 2005.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Georgetown, 2101
Wisconsin Avenue NW., Washington, DC
20007.
Contact Person: Shamala K. Srinivas, PhD,
Scientific Review Administrator, Grants
Review Branch, Division of Extramural
Activities, National Cancer Institute, National
Institutes of Health, 6116 Executive
Boulevard, Room 8133, Bethesda, MD 20892,
301–594–1224.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 4, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15941 Filed 8–10–05; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (U.S.C. Appendix 2), notice is
hereby given of the National Heart,
Lung, and Blood Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Advisory Council.
Date: September 16, 2005.
Open: 8:30 a.m. to 12 p.m.
Agenda: Discussion of program policies
and issues.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room E1
and E2, Bethesda, MD 20892.
Closed: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room E1
and E2, Bethesda, MD 20892.
Contact Person: Deborah P. Beebe, PhD,
Director, Division of Extramural Affairs,
National Heart, Lung, and Blood Institute,
National Institutes of Health, Two Rockledge
Center, Room 7100, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 435–0260.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business of professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for
entrance into the building by nongovernment employees. Persons without
a government I.D. will need to show a
photo I.D. and sign-in at the security
desk upon entering the building.
E:\FR\FM\11AUN1.SGM
11AUN1
46880
Federal Register / Vol. 70, No. 154 / Thursday, August 11, 2005 / Notices
Information is also available on the
Institute’s/Center’s home page: https://
www.nhlbi.nih.gov/meetings/index.htm,
where an agenda and any additional
information for the meeting will be
posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: August 4, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15942 Filed 8–10–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Diabetes
Complications in Animals.
Date: September 1, 2005.
Time: 11:00 a.m. to 1 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Maxine A. Lesniak, MPH,
Scientific Review Administrator, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 756, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7792. lesniakm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
VerDate jul<14>2003
16:14 Aug 10, 2005
Jkt 205001
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 4, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15940 Filed 8–10–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Council for
Biomedical Imaging and Bioengineering.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering.
Date: September 14, 2005.
Open: 8 a.m. to 12:30 p.m.
Agenda: Report of the Director; Strategic
Plan Development; Training and Career
Development; Staff and Guest Speaker
Scientific Presentations.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Closed: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Mariott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Anthony Demsey, PhD,
Director, Office of Extramural Policy,
National Institute of Biomedical Imaging and
Bioengineering, 6701 Democracy Blvd, Room
241, Bethesda, MD 20892.
Any interested person may file
written comments with the committee
by forwarding the statement to the
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Contact Person listed on the notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib1.nih.gov/about/nacbib/
nacbib.htm, where an agenda and any
additional information for the meeting
be posted when available.
Dated: August 3, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15943 Filed 8–10–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Child Health and
Human Development; Amended Notice
of Meeting
Notice is hereby given of a change in
the meeting of the National Institutes of
Child Health and Human Development
Special Emphasis Panel, July 27, 2005,
1 p.m. to July 27, 2005, 1:30 p.m.
National Institutes of Health, 6100
Executive Boulevard, 5th Floor
Conference Room, Rockville, MD, 20852
which was published in the Federal
Register on July 22, 2005, 70 FR 42354.
The meting will be held August 9,
2005 at 12 p.m. to 12:30 p.m. The
meeting is closed to the public.
Dated: August 4, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15944 Filed 8–10–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Neurological
Disorders and Stroke Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 70, Number 154 (Thursday, August 11, 2005)]
[Notices]
[Pages 46879-46880]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15942]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (U.S.C. Appendix 2), notice is hereby given of the National
Heart, Lung, and Blood Advisory Council.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Advisory
Council.
Date: September 16, 2005.
Open: 8:30 a.m. to 12 p.m.
Agenda: Discussion of program policies and issues.
Place: National Institutes of Health, Natcher Building, 45
Center Drive, Room E1 and E2, Bethesda, MD 20892.
Closed: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Natcher Building, 45
Center Drive, Room E1 and E2, Bethesda, MD 20892.
Contact Person: Deborah P. Beebe, PhD, Director, Division of
Extramural Affairs, National Heart, Lung, and Blood Institute,
National Institutes of Health, Two Rockledge Center, Room 7100, 6701
Rockledge Drive, Bethesda, MD 20892, (301) 435-0260.
Any interested person may file written comments with the committee
by forwarding the statement to the Contact Person listed on this
notice. The statement should include the name, address, telephone
number and when applicable, the business of professional affiliation of
the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance into the building by non-government employees.
Persons without a government I.D. will need to show a photo I.D. and
sign-in at the security desk upon entering the building.
[[Page 46880]]
Information is also available on the Institute's/Center's home
page: https://www.nhlbi.nih.gov/meetings/index.htm, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: August 4, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-15942 Filed 8-10-05; 8:45 am]
BILLING CODE 4140-01-M
